Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Cornell Researchers Target Coronavirus Membrane Fusion Mechanism for Antiviral Development

By HospiMedica International staff writers
Posted on 18 Apr 2020
A team of researchers from Cornell University (Ithaca, NY, USA) has proposed that blocking membrane fusion – a critical part of the mechanism by which coronaviruses spread – could offer a potential target for antiviral treatment for COVID-19.

The researchers initially set out to analyze the structure and characteristics of SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus), with a focus on the spike protein – specifically the fusion peptide – that allows these viruses to infect cells by transferring their genome. More...
As the current pandemic escalated, the researchers compared the biological sequences of the fusion peptides of SARS-CoV to SARS-CoV-2, the virus that causes COVID-19, and found them to be a 93% match.

According to the researchers, blocking the fusion step is significant as the fusion machinery does not evolve and change as fast as other parts of the protein does. It has been built specifically to merge the two membranes together and developing antiviral strategies to reduce that efficiency could potentially result in very broadly-acting treatments. The team of researchers is now drilling down into the intricate procedure of membrane fusion, or the mechanism by which coronaviruses spread.

Membrane fusion is a multistep process that begins with the virus recognizing that it’s found the right type of cell to infect. To do this, the virus receives feedback from the chemical environment, including cues like the receptor that the host cell presents. The virus then attaches to the host cell receptor by way of the spike protein. Next, a piece of the spike protein, called the fusion peptide, interacts directly with the host cell membrane and facilitates merging to form a fusion pore, or opening. The virus then transfers its genome into the host cell through this pore. These genomic instructions essentially commandeer the host’s machinery to produce more viruses. These interactions can be difficult to parse through traditional approaches because the fusion process is dynamic and flexible, and the spike protein changes its shape drastically during fusion.

The researchers then used a variety of spectroscopic methods, including electron spin resonance and nuclear magnetic resonance, respectively, to more closely analyze the fusion peptide’s structure and function. They found that calcium ions interacting with the fusion peptide can change the peptide’s structure, and how it interacts with membranes in ways that promote infection in MERS and SARS. The researchers are now turning their attention to SARS-CoV-2 as the fusion peptides are consistent in all three viruses. The team is hopeful the research can illuminate some of the chemistry-related questions surrounding COVID-19, such as how it was able to move into humans, what chemical cues facilitated that process, and why the virus is able to replicate so easily in the respiratory tract.

“The subtleties are what make this virus so interesting. For some viruses, calcium has no effect on infection, but for coronavirus, we are seeing that it does,” said Susan Daniel, associate professor of chemical and biomolecular engineering, who led the multidisciplinary group. “And this points us to thinking about how this might be a target for developing antiviral drugs or repurposing already approved calcium-blocking drugs. Based on what we know, we believe that targeting the fusion machinery for drug development is an astute choice.”

Related Links:
Cornell University


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.